GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
P

Proteina Co 468530.KQ · KRW

Health Care · KOSDAQ · 🇰🇷 South Korea

Compare

58,800

+6.91%

Close of 9 Nov 2026, in KRW

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in KRW, from our data supplier.

FY2025

Revenue

₩2.95bn

FY2022FY2025

Net income

−₩9.01bn

FY2022FY2025

Free cash flow

−₩9.58bn

FY2022FY2025

Shareholders' equity

₩28.37bn

FY2022FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022
Revenue₩2.95bn₩2.30bn₩578.1m₩465.6m
Research and development₩7.42bn₩5.80bn₩3.14bn₩1.24bn
Operating income−₩11.37bn−₩9.12bn−₩7.26bn−₩5.38bn
Net income−₩9.01bn−₩5.73bn−₩22.79bn−₩11.37bn
Diluted earnings per share-823.80-531.71-2,112.88-1,054.36

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022
Total assets₩31.75bn₩17.97bn₩24.01bn₩13.32bn
Total liabilities₩3.38bn₩2.21bn₩76.50bn₩43.74bn
Debt—₩1.01bn₩16.68bn₩5.70bn
Shareholders' equity₩28.37bn₩15.76bn−₩52.49bn−₩30.42bn
Shares outstanding11m11m11m11m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022
Cash from operations−₩8.07bn−₩6.08bn−₩5.68bn−₩3.52bn
Capital spending−₩1.51bn−₩2.32bn−₩293.2m−₩1.12bn
Free cash flow−₩9.58bn−₩8.40bn−₩5.98bn−₩4.64bn

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024
Revenue₩349.3m₩168.6m₩343.3m₩582.2m₩963.6m₩1.06bn₩2.30bn
Operating income−₩3.96bn−₩4.71bn−₩4.45bn−₩2.95bn−₩2.40bn−₩1.58bn−₩9.12bn
Net income−₩3.11bn−₩3.28bn−₩3.04bn−₩2.57bn−₩1.96bn−₩1.45bn−₩5.73bn
Diluted earnings per share-284.47-300.01-277.87-236.04-181.48-134.34-531.71
Cash from operations−₩2.07bn−₩2.23bn−₩2.44bn−₩3.56bn−₩773.0m−₩1.30bn−₩6.08bn
Capital spending−₩228.0m−₩548.0m−₩259.0m−₩819.0m−₩182.0m−₩244.0m−₩2.32bn
Free cash flow−₩2.29bn−₩2.78bn−₩2.70bn−₩4.38bn−₩955.0m−₩1.54bn−₩8.40bn
Total assets₩26.46bn₩28.69bn₩31.75bn₩33.48bn₩15.33bn₩16.44bn—
Shareholders' equity₩22.69bn₩25.22bn₩28.37bn₩30.97bn₩12.53bn₩14.41bn—

Financial ratios

Data as of 30 Aug 2026

FY2025FY2024FY2023FY2022
Operating margin-385.2%-396.5%-1255.1%-1155.3%
Net margin-305.4%-249.2%-3941.3%-2442.0%
Return on equity-31.8%-36.4%43.4%37.4%
Return on assets-28.4%-31.9%-94.9%-85.4%
Revenue growth28.3%298.0%24.2%—
Earnings growth57.2%-74.8%100.4%—
Current ratio15.15x15.37x0.37x0.38x
Equity ratio89.4%87.7%-218.6%-228.4%
Interest coverage-100.90x-2.99x-2.63x-2.47x
R&D as a share of sales251.5%252.0%542.9%265.3%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue85.1%——
Operating income28.3%——
Net income-7.5%——

Valuation history

At each fiscal year end

FY2025
Price to earnings-134.3
Price to sales410.0

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.